BIIB Biogen
8-K Current Report
Filed: March 11, 2026
Health Care
Biological Products, (No Diagnostic Substances)Biogen (BIIB) 8-K current report filed with SEC EDGAR on March 11, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 5.02: Departure/Election of Directors or Officers
AI Filing Analysis8-K
Item 5.02 · Departure/Election of Directors or Officers
- • Susan H. Alexander, Chief Legal Officer, departing Biogen effective end of May 2026
- • CLO search initiated; no interim successor named, creating near-term leadership gap in legal function
Get deeper insights on Biogen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.